Joel D. Leverson

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Andrew J. Souers, Joel D. Leverson, Erwin R. Boghaert et al. · Nature Medicine · 2013 · 3K citations

Medicine, Oncology, Pharmacology +10

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

Marina Konopleva, Daniel A. Pollyea, Jalaja Potluri et al. · Cancer Discovery · 2016 · 1.1K citations · Full text

Medicine, Hematology, Pharmacology +17

The Tyrosine Kinase Negative Regulator c-Cbl as a RING-Type, E2-Dependent Ubiquitin-Protein Ligase

Claudio A.P. Joazeiro, Simon S. Wing, Han-kuei Huang et al. · Science · 1999 · 1K citations

Life Sciences, Biochemistry, Molecular Biology +17

Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia

Rongqing Pan, Leah J. Hogdal, Juliana M. Benito et al. · Cancer Discovery · 2013 · 735 citations · Full text

Life Sciences, Oncology, Pharmacology +17

Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy

Joel D. Leverson, Darren C. Phillips, Michael J. Mitten et al. · Science Translational Medicine · 2015 · 541 citations · Full text

Medicine, Oncology, Pharmacology +14